title: Integration of virtual and high throughput screening in lead discovery settings.
abstract: In the last decade mass screening strategies became the main source of leads in drug discovery settings. Although high throughput (HTS) and virtual screening (VS) realize the same concept the different nature of these lead discovery strategies (experimental vs theoretical) results that they are typically applied separately. The majority of drug leads are still identified by hit-to-lead optimization of screening hits. Structural information on the target as well as on bound ligands, however, make structure-based and ligand-based virtual screening available for the identification of alternative chemical starting points. Although, the two techniques have rarely been used together on the same target, here we review the existing prominent studies on their true integration. Various approaches have been shown to apply the combination of HTS and VS and to better use them in lead generation. Although several attempts on their integration have only been considered at a conceptual level, there are numerous applications underlining its relevance that early-stage pharmaceutical drug research could benefit from a combined approach.
authors.affiliation: Gedeon Richter Plc, P.O. Box 27, H-1475 Budapest, Hungary.
authors.forename: Tímea
authors.initials: T
authors.lastname: Polgár
authors.forename: György M
authors.initials: GM
authors.lastname: Keseru
mesh_terms: D000818:Animals; D055808:Drug Discovery; D057166:High-Throughput Screening Assays / Q000379:methods*; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D010600:Pharmacology
chemical_list: D008024:Ligands; D004364:Pharmaceutical Preparations